ESC working group cellular biology of the heart : position paper: improving the preclinical assessment of novel cardioprotective therapies
Lecour, Sandrine (Hatter Institute for Cardiovascular Research (Àfrica))
Bøtker, Hans Erik (Aarhus University Hospital (Aarhus, Dinamarca))
Condorelli, Gianluigi (Instituto Clinico Humanitas (Milano, Itàlia))
Davidson, Sean M. (Hatter Institute for Cardiovascular Research (Londres, Regne Unit))
García-Dorado, David (Universitat Autònoma de Barcelona)
Engel, Felix B. (Friedrich-Alexander-Universität Erlangen-Nürnberg)
Ferdinandy, Péter (Semmelweis Egyetem. Department of Pharmacology and Pharmacotherapy)
Heusch, Gerd (Universitätsklinikum Essen)
Madonna, Rosalinda (Università degli Studi "G. d'Annunzio" Chieti)
Ovize, Michel (Université Claude Bernard Lyon 1)
Ruiz Meana, Marisol (Hospital Universitari Vall d'Hebron)
Schulz, Rainer (Justus Liebig-Universität Gießen)
Sluijter, Joost P. G. (Universitair Medisch Centrum Utrecht)
Van Laake, Linda W. (Universitair Medisch Centrum Utrecht)
Yellon, Derek M. (Hatter Institute for Cardiovascular Research (Londres, Regne Unit))
Hausenloy, Derek J. (Hatter Institute for Cardiovascular Research (Londres, Regne Unit))

Data:	2014
Resum:	Ischaemic heart disease (IHD) remains the leading cause of death and disability worldwide. As a result, novel therapies are still needed to protect the heart from the detrimental effects of acute ischaemia-reperfusion injury, in order to improve clinical outcomes in IHD patients. In this regard, although a large number of novel cardioprotective therapies discovered in the research laboratory have been investigated in the clinical setting, only a few of these have been demonstrated to improve clinical outcomes. One potential reason for this lack of success may have been the failure to thoroughly assess the cardioprotective efficacy of these novel therapies in suitably designed preclinical experimental animal models. Therefore, the aim of this Position Paper by the European Society of Cardiology Working Group Cellular Biology of the Heart is to provide recommendations for improving the preclinical assessment of novel cardioprotective therapies discovered in the research laboratory, with the aim of increasing the likelihood of success in translating these new treatments into improved clinical outcomes.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Cardioprotection ; Myocardial infarction ; Animal models ; Ischaemia ; Reperfusion
Publicat a:	Cardiovascular research, Vol. 104, issue 3 (Dec. 2014) , p. 399-411, ISSN 1755-3245

DOI: 10.1093/cvr/cvu225
PMID: 25344369

13 p, 340.4 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats